Feb. 11 at 2:41 AM
$ABCL Hard not to be. ABCL is losing between
$20 and
$50 million per quarter, that
$1 billion cash stack from IPO and covid drug sales is almost gone, only
$108 million left. That means that dilution to raise more cash to fund operations will start this year, with such a low share price that means it will be under
$1 from the dilution eventually and will have to reverse split, dilute more etc, the dilution death spiral most biotech stocks end. I thought when they built up over 5 years cash runway in 2020/2021 that would be plenty of time for them to create another money making drug or at least have one in trials but alas here we are. I wish I was wrong but this is just the facts about the money situation here, dilution and lower share prices are inevitable as ABCL doesn't even have a drug in phase 3 trials yet, so they are many years from making any drug revenue, if any at all.
